NSCLC & Targeted Therapy: A Brief Overview and Update in the Metastatic Setting
By
Memorial Sloan Kettering Cancer Center
FEATURING
Michael Hwang
By
Memorial Sloan Kettering Cancer Center
FEATURING
Michael Hwang
Disclaimers:
On March 1, 2024, The FDA has approved RYBREVANT® (amivantamab-vmjw) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
On August 19, 2024, the FDA approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
On March 1, 2024, The FDA has approved RYBREVANT® (amivantamab-vmjw) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
On August 19, 2024, the FDA approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Comments 0
Login to view comments.
Click here to Login
